切换至 "中华医学电子期刊资源库"

中华普通外科学文献(电子版) ›› 2022, Vol. 16 ›› Issue (03) : 225 -230. doi: 10.3877/cma.j.issn.1674-0793.2022.03.015

综述

尿液检测在原发性肝癌中的应用
张宇珂1, 杜顺达1,(), 毛一雷1   
  1. 1. 100730 北京,中国医学科学院 北京协和医学院 北京协和医院肝脏外科
  • 收稿日期:2022-03-25 出版日期:2022-06-01
  • 通信作者: 杜顺达
  • 基金资助:
    中国医学科学院医学与健康科技创新工程项目(CIFMS 2021-I2M-1-014)

Urinalysis in primary hepatic carcinoma

Yuke Zhang1, Shunda Du1,(), Yilei Mao1   

  1. 1. Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
  • Received:2022-03-25 Published:2022-06-01
  • Corresponding author: Shunda Du
引用本文:

张宇珂, 杜顺达, 毛一雷. 尿液检测在原发性肝癌中的应用[J]. 中华普通外科学文献(电子版), 2022, 16(03): 225-230.

Yuke Zhang, Shunda Du, Yilei Mao. Urinalysis in primary hepatic carcinoma[J]. Chinese Archives of General Surgery(Electronic Edition), 2022, 16(03): 225-230.

近年来,原发性肝癌发病率逐年上升,因起病隐匿,早期发现、诊断困难,临床上急需一些简便有效的检测方法用以筛查、诊断。尿液中含有丰富的蛋白质、循环核酸、代谢物等,且获取无创、便捷、可重复。目前已经有研究发现检测尿液中各种特异性和非特异性产物,能够应用于原发性肝癌的筛查、诊断、判断预后及长期监测,随着方法学的进步,将来可能在日常生活中推广,从而获得早发现、早诊断。本文对尿液中常用于检测的各组分及其相关的研究结果进行阐述。

In recent years, the incidence of primary hepatic carcinoma has been increasing year by year, the insidious onset of primary hepatic carcinoma increases the difficulty of early detection and diagnosis. Simple and effective detection methods are urgently needed for screening and diagnosis in clinical practice. Urine is rich in protein, circulating nucleic acids, metabolites, and its acquisition is non-invasive, convenient and repeatable. Studies have found that the detection of various specific and non-specific products in urine plays a crucial role in screening, diagnosis, evaluating prognosis and long-term monitoring of primary hepatic carcinoma. With the advancement of methodology, it may be promoted in daily life in the future, so as to obtain early detection and early diagnosis. This article will describe the components commonly used for detection in urine and their related research results.

[1]
Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012[J]. Cancer, 2020, 126(11): 2666-2678.
[2]
陈圣, 陈国想, 何中明, 等. 微小RNA在胆管癌发生发展中的作用[J]. 临床肝胆病杂志, 2021, 37(9): 2241-2245.
[3]
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[4]
European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236.
[5]
Boerner T, Drill E, Pak LM, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma[J]. Hepatology, 2021, 74(3): 1429-1444.
[6]
Dinges SS, Hohm A, Vandergrift LA, et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations[J]. Nat Rev Urol, 2019, 16(6): 339-362.
[7]
Hirotsu T, Sonoda H, Uozumi T, et al. A highly accurate inclusive cancer screening test using caenorhabditis elegans scent detection[J]. PLoS One, 2015, 10(3): e0118699.
[8]
Guan MC, Ouyang W, Wang MD, et al. Biomarkers for hepatocellular carcinoma based on body fluids and feces[J]. World J Gastrointest Oncol, 2021, 13(5): 351-365.
[9]
Tsai JF, Jeng JE, Chuang LY, et al. Clinical evaluation of urinary transforming growth factor-beta1 and serum alpha-fetoprotein as tumour markers of hepatocellular carcinoma[J]. Br J Cancer, 1997, 75(10): 1460-1466.
[10]
Abdalla MA, Haj-Ahmad Y. Promising urinary protein biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients[J]. J Cancer, 2012, 3: 390-403.
[11]
Chiou SH, Lee KT. Proteomic analysis and translational perspective of hepatocellular carcinoma: identification of diagnostic protein biomarkers by an onco-proteogenomics approach[J]. Kaohsiung J Med Sci, 2016, 32(11): 535-544.
[12]
Zhan Z, Guan Y, Mew K, et al. Urine α-fetoprotein and orosomucoid 1 as biomarkers of hepatitis B virus-associated hepatocellular carcinoma[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 318(2): G305-G312.
[13]
Zhao Y, Li Y, Liu W, et al. Identification of noninvasive diagnostic biomarkers for hepatocellular carcinoma by urinary proteomics[J]. J Proteomics, 2020, 225: 103780.
[14]
Metzger J, Negm AA, Plentz RR, et al. Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders[J]. Gut, 2013, 62(1): 122-130.
[15]
Duangkumpha K, Stoll T, Phetcharaburanin J, et al. Urine proteomics study reveals potential biomarkers for the differential diagnosis of cholangiocarcinoma and periductal fibrosis[J]. PLoS One, 2019, 14(8): e0221024.
[16]
Decramer S, Gonzalez de Peredo A, Breuil B, et al. Urine in clinical proteomics[J]. Mol Cell Proteomics, 2008, 7(10): 1850-1862.
[17]
Aitekenov S, Gaipov A, Bukasov R. Review: detection and quantification of proteins in human urine[J]. Talanta, 2021, 223(Pt 1): 121718.
[18]
Jain S, Lin SY, Song W, et al. Urine-based liquid biopsy for nonurological cancers[J]. Genet Test Mol Biomarkers, 2019, 23(4): 277-283.
[19]
Kim AK, Hamilton JP, Lin SY, et al. Urine DNA biomarkers for hepatocellular carcinoma screening[J]. Br J Cancer, 2022, 126(10): 1432-1438.
[20]
Liu Z, Wang Y, Dou C, et al. MicroRNA-1468 promotes tumor progression by activating PPAR-γ-mediated AKT signaling in human hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2018, 37(1): 49.
[21]
Zhang Z, Zhang Y, Sun XX, et al. MicroRNA-146a inhibits cancer metastasis by downregulating VEGF through dual pathways in hepatocellular carcinoma[J]. Mol Cancer, 2015, 14: 5.
[22]
Ye Y, Zhuang J, Wang G, et al. MicroRNA-495 suppresses cell proliferation and invasion of hepatocellular carcinoma by directly targeting insulin-like growth factor receptor-1[J]. Exp Ther Med, 2018, 15(1): 1150-1158.
[23]
Abdalla MA, Haj-Ahmad Y. Promising candidate urinary microRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients[J]. J Cancer, 2012, 3: 19-31.
[24]
Świtlik WZ, Bielecka-Kowalska A, Karbownik MS, et al. Forms of diagnostic material as sources of miRNA biomarkers in hepatocellular carcinoma: A preliminary study[J]. Biomark Med, 2019, 13(7): 523-534.
[25]
Zhou G, Zeng Y, Luo Y, et al. Urine miR-93-5p is a promising biomarker for early detection of HBV-related hepatocellular carcinoma[J]. Eur J Surg Oncol, 2022, 48(1): 95-102.
[26]
Silakit R, Loilome W, Yongvanit P, et al. Urinary microRNA-192 and microRNA-21 as potential indicators for liver fluke-associated cholangiocarcinoma risk group[J]. Parasitol Int, 2017, 66(4): 479-485.
[27]
Kobori K, Sakakibara H, Maruyama K, et al. A rapid method for determining urinary indoleacetic acid concentration and its clinical significance as the tumor-marker in the diagnosis of malignant diseases[J]. J UOEH, 1983, 5(2): 213-220.
[28]
Saichua P, Yakovleva A, Kamamia C, et al. Levels of 8-OxodG predict hepatobiliary pathology in opisthorchis viverrini endemic settings in Thailand[J]. PLoS Negl Trop Dis, 2015, 9(7): e0003949.
[29]
Nanashima A, Izumino H, Sumida Y, et al. Relationship between urinary 8-hydroxydeoxyguanine (8-OhdG) levels and clinicopathological findings in hepatobiliary malignancies[J]. Anticancer Res, 2016, 36(8): 3899-3903.
[30]
Yuan JM, Grouls M, Carmella SG, et al. Prediagnostic levels of urinary 8-epi-prostaglandin F2α and prostaglandin E2 metabolite, biomarkers of oxidative damage and inflammation, and risk of hepatocellular carcinoma[J]. Carcinogenesis, 2019, 40(8): 989-997.
[31]
Ladep NG, Dona AC, Lewis MR, et al. Discovery and validation of urinary metabotypes for the diagnosis of hepatocellular carcinoma in West Africans[J]. Hepatology, 2014, 60(4): 1291-1301.
[32]
Haznadar M, Diehl CM, Parker AL, et al. Urinary metabolites diagnostic and prognostic of intrahepatic cholangiocarcinoma[J]. Cancer Epidemiol Biomarkers Prev, 2019, 28(10): 1704-1711.
[33]
Sun L, Su Y, Liu X, et al. Serum and exosome long non-coding RNAs as potential biomarkers for hepatocellular carcinoma[J]. J Cancer, 2018, 9(15): 2631-2639.
[34]
Lapitz A, Arbelaiz A, O’Rourke CJ, et al. Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis[J]. Cells, 2020, 9(3): 721.
[35]
Kim J, Kang W, Sinn DH, et al. Substantial risk of recurrence even after 5 recurrence-free years in early-stage hepatocellular carcinoma patients[J]. Clin Mol Hepatol, 2020, 26(4): 516-528.
[36]
Dhanasekaran R, Hemming AW, Zendejas I, et al. Treatment outcomes and prognostic factors of intrahepatic cholangio-carcinoma[J]. Oncol Rep, 2013, 29(4): 1259-1267.
[37]
Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates[J]. Chin Clin Oncol, 2018, 7(5): 52.
[1] 代雯荣, 赵丽娟, 李智慧. 细胞外囊泡对胚胎着床影响的研究进展[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 616-620.
[2] 罗丹, 孔为民, 陈姝宁, 赵小玲, 谢云凯. 子宫内膜异位症患者在位及异位内膜上皮细胞-间充质转化相关生物标志物的变化[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 530-539.
[3] 魏徐, 张鸽, 伍金林. 新生儿脓毒症相关性凝血病的监测和治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 379-386.
[4] 李越洲, 张孔玺, 李小红, 商中华. 基于生物信息学分析胃癌中PUM的预后意义[J]. 中华普通外科学文献(电子版), 2023, 17(06): 426-432.
[5] 杨倩, 李翠芳, 张婉秋. 原发性肝癌自发性破裂出血急诊TACE术后的近远期预后及影响因素分析[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 33-36.
[6] 李腾成, 狄金明. 2023 V1版前列腺癌NCCN指南更新要点解读[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 313-318.
[7] 杜静怡, 徐兴祥. 循环肿瘤细胞在非小细胞肺癌中的研究进展[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 596-600.
[8] 陈坤, 何傅梅, 方婷, 陈文瑞. 血清sCD73与EGFR/ALK野生型非小细胞肺癌免疫治疗效果的相关性分析[J]. 中华肺部疾病杂志(电子版), 2023, 16(04): 504-507.
[9] 陈安, 冯娟, 杨振宇, 杜锡林, 柏强善, 阴继凯, 臧莉, 鲁建国. 基于生物信息学分析CCN4在肝细胞癌中表达及其临床意义[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 702-707.
[10] 韩冰, 顾劲扬. 深度学习神经网络在肝癌诊疗中的研究及应用前景[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 480-485.
[11] 葛云鹏, 崔红元, 宋京海. 人工智能在原发性肝癌诊断、治疗及预后中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 367-371.
[12] 赫嵘, 贾哲, 张珂, 李代京, 张萌, 蒋力. 基于PSM分析腹腔镜肝切除联合Hassab术治疗合并门静脉高压症肝癌疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 376-383.
[13] 吴蓉菊, 向平超. COPD频繁急性加重表型与炎性因子相关性研究[J]. 中华临床医师杂志(电子版), 2023, 17(9): 939-947.
[14] 蔡荇, 郑瑞强. 肝素结合蛋白在脓毒症中的应用及研究进展[J]. 中华临床医师杂志(电子版), 2023, 17(04): 487-490.
[15] 郭芳芳, 李珉珉. 狼疮肾炎无创生物标志物的研究进展[J]. 中华诊断学电子杂志, 2023, 11(04): 271-275.
阅读次数
全文


摘要